Kleiner Perkins backs iZumi Bio's stem cell research

06/17/2008 | San Francisco Chronicle

Kleiner Perkins Caufield & Byers will invest in iZumi Bio, a biotech firm working on reprogramming adult cells to regain the properties of embryonic stem cells. IZumi announced Monday that it will collaborate with the J. David Gladstone Institutes in San Francisco to focus on research involving "induced pluripotent stem cells."

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA